Lilly expands Gate deal. Eli Lilly stock gains 1.60 percent.

Published on 10/07/2026 at 15:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gate deal potential reaches USD 870.00 million. Eli Lilly stock costs EUR 1,046.20 on October 7, 2026 versus EUR 1,029.70.

Schwarzweiß-Reportagefoto von Mitarbeitern an einer Tablettenproduktionslinie — Dokumentarische Schwarzweiß-Aufnahme repräsentiert Eli Lilly and Company, ISIN US5324571083, in pharmazeutischer Produktionsstätte weltweit, Illustration mit AI erstellt.

Eli Lilly and Co. (ISIN US5324571083) was trading at EUR 1,046.20 at Lang & Schwarz on October 7, 2026 at 3:07 p.m. CEST, plus 1.60 percent versus the prior close of EUR 1,029.70. As Yahoo Finance reported on October 6, 2026, Lilly expanded its Gate Bioscience partnership, with potential milestone payments of USD 870.00 million. The agreement adds one drug target and an option for a second.

Gate deal adds pipeline capacity

Gate Bioscience will lead discovery work, while Lilly will handle later-stage development, manufacturing and commercialization under the expanded agreement. Lilly also receives exclusive worldwide rights to products developed for the selected targets, giving the deal a longer-term pipeline dimension beyond the initial payment structure.

Foundayo delivers two risk figures

In a release dated October 1, 2026, Eli Lilly and Company said post-hoc ATTAIN-1 analyses associated Foundayo 17.2 mg with a predicted 57.00 percent reduction in 10-year type 2 diabetes risk versus placebo at 72 weeks. The same dose was associated with an 18.00 percent reduction in predicted cardiovascular disease risk versus placebo, although both figures are model-based clinical analyses rather than commercial revenue.

Revenue growth sets a high bar

MarketBeat reported that Eli Lilly generated USD 22.97 billion of revenue in the second quarter of 2026, up 47.70 percent year over year, while earnings per share reached USD 8.38 versus a USD 6.40 consensus estimate. The result explains why pipeline announcements are judged against an already demanding growth profile: the company must convert research spending into products that can extend this revenue pace.

The next test is scheduled for October 29, 2026. Zacks identifies that date as the confirmed release date for the quarter ending September 2026 and lists a consensus earnings estimate of USD 9.83 per share. The finance quote showed a USD 1.1 trillion market capitalization on October 6, 2026, with a 52-week range of USD 783.85 to USD 1,292.65.

Euro quote gains against prior close

At Lang & Schwarz, Eli Lilly stock was trading at EUR 1,046.20 on October 7, 2026 at 3:07 p.m. CEST, up EUR 16.50 or 1.60 percent versus the Lang & Schwarz prior close of EUR 1,029.70 on October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.